<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574925</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-QBE-0201</org_study_id>
    <nct_id>NCT00574925</nct_id>
  </id_info>
  <brief_title>Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate whether eradication treatment of&#xD;
      Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the&#xD;
      time to relapse in patients with gastroesophageal reflux disease (GERD).&#xD;
&#xD;
      A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within 14&#xD;
      days that are equal or above the critical value of 25.&#xD;
&#xD;
      The secondary objectives are&#xD;
&#xD;
        1. To compare the time to relapse in the two H. pylori positive study groups with the H.&#xD;
           pylori negative control group&#xD;
&#xD;
        2. To compare the pattern of inflammation and atrophy in the two H. pylori positive&#xD;
           treatment groups with the naturally H. pylori negative control group at relapse.&#xD;
&#xD;
        3. All the above objectives analyzed for the efficacy subset that is the per-protocol&#xD;
           patients broken down by effective H. pylori-eradication.&#xD;
&#xD;
      Secondary endpoints will be analyzed by the following parameters and their interactions:&#xD;
&#xD;
        1. Treatment : Eradicated, Non-eradicated, Hp-negative control&#xD;
&#xD;
        2. Esophagitis at study start: grades 0, A/B and C/D&#xD;
&#xD;
        3. Gender&#xD;
&#xD;
        4. Alcohol intake&#xD;
&#xD;
        5. NSAID/ASA intake (for histological results)&#xD;
&#xD;
             -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date>October 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        For inclusion in the study the subject must fulfill all of the following criteria:&#xD;
&#xD;
          1. Patients aged between 18 and 70 years.&#xD;
&#xD;
          2. Chronic symptoms (&gt;8 weeks) suggestive for GERD, as defined in Table 2 with or without&#xD;
             reflux esophagitis grade A-D (Los Angeles classification)&#xD;
&#xD;
          3. Indication for endoscopy due to GERD symptoms is given&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Table 2: Lead GERD criteria&#xD;
&#xD;
        For inclusion in the study, all of the following lead GERD criteria should hold:&#xD;
&#xD;
          -  At least one of the symptoms heartburn or regurgitation.&#xD;
&#xD;
          -  At least 8 weeks ongoing symptoms.&#xD;
&#xD;
          -  At least 3 times a week.&#xD;
&#xD;
          -  At least moderate intensity, corresponding to light impairment in daily life and&#xD;
             occasional need for drugs.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Any of the following is regarded as a criterion for exclusion from the study:&#xD;
&#xD;
          1. Severe organic esophageal disease other than reflux esophagitis (e.g. carcinoma,&#xD;
             esophageal stenosis).&#xD;
&#xD;
          2. Gastric or duodenal ulcers&#xD;
&#xD;
          3. Patients with visible Barrett's mucosa; no histological confirmation is required for&#xD;
             exclusion&#xD;
&#xD;
          4. History of previous esophageal or gastric surgery&#xD;
&#xD;
          5. Alcohol or drug abuse&#xD;
&#xD;
          6. Severe organic or psychiatric disease&#xD;
&#xD;
          7. Pregnancy or lactation&#xD;
&#xD;
          8. Women with child-bearing potential if no medically accepted contraceptive measures are&#xD;
             used&#xD;
&#xD;
          9. Contra-indication to amoxicillin, clarithromycin or esomeprazole (Nexium)&#xD;
&#xD;
         10. Need for concomitant medication which could interfere with the investigational&#xD;
             products (substrates of CYP3A4)&#xD;
&#xD;
         11. Suspected or confirmed poor compliance&#xD;
&#xD;
         12. Participation in a clinical study within 8 weeks prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Schwizer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2007</last_update_posted>
  <keyword>H. pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

